RE:RE:RE:RE:Great I suspect the reason for that is the company knows we who follow the company closely are anxious for LSA to get going and thus they alerted us to the 6/21 meeting earlier than what normally would be the case. And they are aware that the way the September announcement of the move to general NASH was handled (no build-up of expectations before hand) meant that few actually heard the news. I am on LSA's mailing list and I have not recieved anything from them yet and really would not expect to get that much notice about a 6/21 KOL webinar.
This is a great step and it should give us some encouragement about the state of the cancer phase I. I imagine they would not be doing this if that trial was a shambles. It will be great to hear what Believieu has to say but I would have been even more intersted if the KOL was someone from outside the company's sphere of consultants. Unfortunately, there may not be many such independent KOL's to draw from at this early stage of TH-1902's development.
The key thing is that LSA somehow manages to get more than our little group interestedd in this KOL meeting. No more preaching to the choir please!
scarlet1967 wrote: I did submit some questions, I find it odd that they didn't issue a PR or posting the news on their social media platforms!
Wino115 wrote: Keep it coming THTX/LSA. Information to aid in evaluating the company's pipeline is crucial. There's a button to send in questinos prior to the event. We should think about the most important issues for the whole SORT1+ and the Phase 1 trial and submit them. Better to get the best questions in so they are answered and not innundate them with too many.
Science minds, start thinking!
SPCEO1 wrote: Excellent news! TH continues to lead with cancer versus NASH which likely indicates things are following an encouraging path so far in the cancer phase I trial.
scarlet1967 wrote: In case you did not receive this already, please see below for information on an upcoming investor event highlighting our SORT1+ Technology, featuring key opinion leader Dr. Richard Beliveau, taking place on Monday, June 21, 2021 at 11:00am ET.
| The webinar will feature a presentation by Key Opinion Leader (KOL) Richard Bliveau, Ph.D. (Universit du Qubec Montral) who will discuss the science of receptor-mediated cancer therapy and the discovery of sortilin as a novel target in cancer treatment. Dr. Bliveau will be available to answer questions following the formal presentations. Theratechnologies' management team will also give an update on their oncology pipeline including TH1902, the Company's lead investigational peptide-drug conjugate (PDC) stemming from its SORT1+ Technology™ in oncology. SORT1+ Technology is a new class of cancer treatment targeting all sortilin-expressing cancers by linking approved anticancer drugs to a proprietary peptide that specifically binds to the sortilin receptor. The PDC is internalized by the sortilin receptor and the therapeutic agent is released directly inside the cancer cell. TH1902 was granted fast track designation by the U.S. Food and Drug Administration (FDA) as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy and is currently being evaluated in a Phase 1 clinical trial. |